Products with Anticancer Bioactivity

Explore BioCrick products associated with Anticancer biological activity, including catalog numbers, product names and available bioactivity information.

Anticancer Bioactivity Products

Cat. No. Product Name
BCN5735 Andrographolide
Andrographolide is an antiinflammatory, antiviral, anti-cancer , hepatoprotective, antithrombotic, hypotensive and antiatherosclerotic drug, it can cure hyperpigmentation disorders. Andrographolide protects against chemical-induced oxidative damage by up-regulating the gene transcription and activity of antioxidant enzymes in various tissues.Andrographolide has potential as a leading compound in the prevention or treatment of obesity and insulin resistance, can ameliorate lipid metabolism and improve glucose use in mice with HFD-induced obesity.
BCN5738 Paeonol
Paeonol has anticancer, anti-inflammatory, antioxidant and cardiovascular protective activities, it shows a novel inhibitory role on neuroinflammation, and presents a new candidate agent for the development of therapies for inflammation-related neurodegenerative diseases. Paeonol suppresses lipopolysaccharide-induced inflammatory cytokines in macrophage cells and protects mice from lethal endotoxin shock. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively; it inhibits PGE₂ synthesis and COX-2 expression, and modulates Sirtuin 1, PKCδ and c-Src signaling pathway.
BCN5740 Costunolide
Costunolide has antipyretic, anti-inflammatory, anti-oxidant, anti-carcinogenic and anti-fungal activities, it possesses normo-glycemic and hypolipidemic activity. Costunolide inhibits RANKL-induced osteoclast differentiation by suppressing RANKL-mediated c-Fos transcriptional activity; it inhibits IL-1beta gene expression by blocking the activation of MAPKs and DNA binding of AP-1; it also induces the ROS-mediated mitochondrial permeability transition and resultant cytochrome c release,
BCN5742 Mollugin
Mollugin is a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Mollugin has anticancer efficacy, can modulate the HER2, HO-1, Nrf2 , and NF- κB pathways.
BCN5743 Myriceric acid B
1. Myriceric acid B is a potent HIV-1 entry inhibitor targeting gp41 and can serve as a lead compound for developing novel anti-HIV-1 drug. 2. Myriceric acid B scavenges DPPH free radicals with IC50 value of 21.8 uM, it inhibits aromatase activity with IC50 value of 6.8 uM, it also exhibits cytotoxic activity towards the MOLT-3 cell line with IC50 values of 3.9 uM.

Items 131 to 135 of 769 total